enzalutamide / Generic mfg. - LARVOL DELTA

Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform. (PubMed, Eur Urol) - "Abiraterone-based treatment intensification did not increase FRH compared to SOC alone. In M1 disease, abiraterone reduced rather than augmented fracture risk, most plausibly reflecting improved metastatic bone disease control."

Journal • P3 data • Genito-urinary Cancer • Musculoskeletal Diseases • Oncology • Prostate Cancer • Solid Tumor

Enzalutamide Plus ADT for the Treatment of mHSPC: Real-World Evidence from a Bulgarian Cohort. (PubMed, Cancers (Basel)) - "While median values were not calculable, estimated PFS and OS were consistent with those in ARCHES. Real-world outcomes from our Bulgarian cohort of patients with mHSPC are largely consistent with those observed among enzalutamide-treated participants in the ARCHES trial."

HEOR • Journal • Real-world evidence • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Pharmacovigilance of Androgen Receptor Pathway Inhibitors in Prostate Cancer: The Impact of Docetaxel Co-Reporting. (PubMed, Cancers (Basel)) - " We analyzed deduplicated U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) reports from 2014 Q1 through 2026 Q1 in which abiraterone, enzalutamide, apalutamide, or darolutamide was the primary suspect drug. Disappearance of darolutamide-associated hematologic signals after documented docetaxel exclusion highlights the value of regimen-level sensitivity analyses in pharmacovigilance of combination cancer therapies. Persistent peripheral neuropathy requires external evaluation because residual confounding from unreported or prior neurotoxic treatment cannot be excluded."

Adverse events • Journal • Fatigue • Genito-urinary Cancer • Hematological Disorders • Oncology • Pain • Prostate Cancer • Solid Tumor

External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial. (PubMed, Cancer) - "The NADIR model demonstrates robust and reproducible discrimination, calibration, and prognostic stratification in a distinct ARPI-treated mHSPC cohort, supporting its potential utility for early response risk stratification and trial enrichment pending prospective validation of model-guided treatment adaptation."

Clinical • Journal • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors. (PubMed, Int J Mol Sci) - "Among AR T878A patients treated with enzalutamide, time to treatment discontinuation (TTD) was longer relative to patients with AR L702H (8 mo (95% CI 4.6-44 mo) vs. 3.5 mo (95% CI 2.3-5.5 mo) log-rank p < 0.0001) or AR amplification (7.7 mo (95% CI 4.7-15.8 mo) vs. 4.8 mo (95% CI 4-5.1 mo) (log-rank p = 0.0034). Among the AR T878A patients treated with abiraterone, TTD was not significantly different relative to patients with AR L702H, but longer relative to patients with AR amplification (7.1 mo (95% CI 5-8.5 mo) vs. 4.2 mo (95% CI 3.5-5.4 mo) (log-rank p = 0.037). This study provides hypothesis generating evidence that outcomes for patients with AR LBD mutations may differ by mutation subtype. AR T878A may be relatively more sensitive to ARPI treatment than AR L702H or amplified AR."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR

Docosahexaenoic Acid Enhances the Cytotoxic Effects of Enzalutamide and the PARP Inhibitor in Castration-Resistant Prostate Cancer Cell Lines. (PubMed, Int J Mol Sci) - "This study investigated the antitumor effects of DHA alone or in combination with enzalutamide (ENZ) or the PARP inhibitor AZD2461 (iP) in CRPC cell lines 22Rv1 and PC3. Wound-healing assays showed that DHA blocked the anti-migratory effects of ENZ and iP in 22Rv1 cells and did not alter iP effects in PC3 cells, indicating epithelial-mesenchymal transition heterogeneity. Overall, DHA potentiates the cytotoxic effects of iP in both models and of ENZ in 22Rv1 cells via differential modulation of cell death in a molecular context-dependent manner."

Journal • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR • PPARG • TNFRSF1A

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=83 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Sep 2028 ➔ May 2030 | Trial primary completion date: Jul 2026 ➔ Feb 2028

Trial completion date • Trial primary completion date • Colon Adenocarcinoma • Colon Cancer • Oncology • Prostate Cancer • Solid Tumor

Tolerance and Efficacy of Enzalutamide in Patients Aged Over 70 Years with Advanced Prostate Cancer: A Single-Center Real-World Experience (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Prognostic Impact of PSMA PET/CT–Based Bone Volumetric Tumor Burden in Metastatic Prostate Cancer Patients Treated with Enzalutamide (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Serum testosterone dynamics in patients with metastatic prostate cancer treated with enzalutamide (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Outcomes of enzalutamide (ENZ) and apalutamide (APA) in metastatic hormone-sensitive prostate cancer (mHSPC): a Canadian real-world (RW) study (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Age-dependent differences in clinical benefit between abiraterone and enzalutamide in mCRPC: a post hoc analysis of the ProBio trial (ESMO 2026) - No abstract available

Clinical • Retrospective data • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Darolutamide (DARO) and enzalutamide (ENZA) in the real-world (RW): Extended Survival and Treatment outcomes in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): DEAR-EST (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Survival Outcomes and Toxicity with Reduced-Dose ARPI Therapy: Rationale for the ENHANCE Phase III Trial (ASTRO 2026) - "Purpose/Objective(s): Androgen receptor pathway inhibitors (ARPIs), including enzalutamide, apalutamide, darolutamide, and abiraterone, are standard systemic therapies for metastatic hormone-sensitive (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). In this real-world cohort, ARPI dose reduction was independently associated with superior OS. This data supports the ENHANCE trial. ENHANCE is a UK multi-centre, open-label, phase III randomised non-inferiority trial comparing reduced-dose ARPI (50% standard dose) versus standard-dose ARPI (100%) in patients with mHSPC or mCRPC."

P3 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Randomized Phase II Study of Enhanced AR Blockade with Enzalutamide In High-Risk Patients with Biochemical Relapse Undergoing Salvage Radiation: Final Results from RTOG 3506 (STEEL) (ASTRO 2026) - "The addition of enzalutamide to standard ADT resulted in an improvement of PFS following SRT that justify a phase 3 trial. The increase in toxicity was consistent with other studies of enzalutamide and did not identify new safety concerns."

Clinical • P2 data • Oncology • AR

N-Terminal Androgen Receptor Antagonists Offer Superior Tumor Suppression on Glioblastoma than C-Terminal Inhibitors (ASTRO 2026) - "While our preliminary data demonstrated good tolerance of the C-terminal AR antagonist (C-ARA) bicalutamide when added to chemoradiotherapy in GBM patients, and animal studies showed excellent tumor control with bicalutamide combined with brain radiotherapy (RT) as a radiosensitizer, bicalutamide (BIC) or enzalutamide (ENZA) in the C-ARA category, when used alone, has resulted in notable failures in mice with orthotopically implanted GBM tumors...ENZA, BIC, and apalutamide (APA) were tested in the C-ARA category. EPI-7386 (EPI) and cinobufagin (CINO) were tested in the N-ARA category... N-ARAs demonstrate higher potency in suppressing GBM proliferation in vitro, with superior effects over C-ARAs in suppressing cancer stem cells and promoting immunostimulation, both of which are essential for GBM therapy. Future in vivo and clinical studies on N-ARAs are warranted."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD133 • IL2 • IL6 • NES • SOX9 • STAT5 • TNFA

Indirect safety comparison of enzalutamide (ENZA) and darolutamide (DARO) with androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Apalutamide and Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Multicentre UK Cohort (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Long-term Patient-reported and Objective Cognitive Effects of Darolutamide vs Enzalutamide in ARACOG (AFT-47) (ESMO 2026) - No abstract available

Clinical • Oncology

Ethnicity-Based Comparative Analysis of Treatment Endpoints of 30,000 Metastatic Castration Resistance Prostate Cancer Patients on Abiraterone and Enzalutamide (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Impact of enzalutamide-related drug–drug interactions on adverse events in the EORTC 1333-GUCG PEACE-3 trial (ESMO 2026) - No abstract available

Adverse events • Oncology

Genetic Dementia Risk and Androgen Receptor (AR) Therapy-associated Cognitive Effects (ARTACE) Results from AFT-47, a Randomized Comparison of Darolutamide (DAR) and Enzalutamide (ENZ) (ESMO 2026) - No abstract available

Clinical • Oncology

Biomarker analysis in the China cohort of the Phase 3 TALAPRO-2 trial of first-line talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) (ESMO 2026) - No abstract available

Biomarker • Clinical • Metastases • P3 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Systemic metabolomics in metastatic castration-resistant prostate cancer patients receiving enzalutamide ± metformin (SAKK 08/14 substudy) (ESMO 2026) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations: safety analyses from the Phase 3 TALAPRO-3 study (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • HRD